Are You Ready For Hefty Rs 25 Dividend By Pharma Stock? Record Date In July; Here’s How to Trade

A subsidiary of the multinational pharmaceutical corporation Novartis, which has had a major presence in India since 1947, is Novartis India. With its two legal businesses, Novartis India Limited and Novartis Healthcare Private Limited, Novartis has a substantial presence in India. With a significant operation in Hyderabad, Novartis India's operations encompass pharmaceutical development, biomedical research, and commercial activities. With a market valuation of Rs 2,084.40 Cr, Novartis India's shares closed Monday's trading session 4.99% higher on the BSE at Rs 844.20 a share. Here is your trade setup to qualify for the substantial dividend of Rs 25 that the small-cap pharmaceutical company has announced.

Novartis India Dividend

"The Board of Directors at its meeting held on Friday, May 09, 2025, had recommended a Final Dividend of INR 25/- per equity share (on Face Value of INR 5/- each) for the Financial Year ended March 31, 2025, subject to the approval of the members at the Annual General Meeting of the Company scheduled to be held on Thursday, July 31, 2025. In continuation to the above and pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Wednesday, July 23, 2025, as the Record Date for determining entitlement of Members to final dividend for the financial year ended March 31, 2025. If the final dividend as recommended by the Board of Directors is approved at the AGM, such dividend will be paid / dispatched, subject to deduction of tax at source after the AGM," said Novartis India in a stock exchange filing.

Novartis India Q4 Results

Novartis India's net profit increased 99.59% to Rs 29.30 crore in the March 2025 quarter from Rs 14.68 crore in the March 2024 quarter. Compared to Rs 81.17 crore in the year-ago quarter, sales increased by 3.34% to Rs 83.88 crore in the quarter under review. EBITDA increased by 59.69% from Rs. 21.63 crore in Q4FY24 to Rs. 34.54 crore in Q4FY25.

Net profit for the entire year increased 18.44% to Rs 100.90 crore in March 2025 compared to Rs 85.19 crore in March 2024. Sales in the year ending March 2025 increased by 6.33% to Rs 356.27 crore, compared to Rs 335.07 crore in the year ending March 2024.

Novartis India Share Price Target

"Novartis India has been trading sideways but is showing signs of accumulation near ₹820-₹830. The stock is attempting to base out after a recent downtrend and could see upside on a breakout above ₹860. Immediate support lies near ₹820 and resistance at ₹880. A close above the resistance may signal a short-term reversal. Traders can consider fresh longs above ₹860 with a stop loss at ₹820 for targets around ₹900. The structure is neutral but improving, with potential to turn bullish on confirmation," commented Riyank Arora - Technical Analyst - Mehta Equities Limited.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.